Deliberate hypoxic pelvic and limb chemoperfusion in the treatment of recurrent melanoma

Stefano Guadagni, Filippo Russo, Carlo Riccardo Rossi, Pier Luigi Pilati, Diego Miotto, Giammaria Fiorentini, Marcello Deraco, Mario Santinami, Giancarlo Palumbo, Marco Valenti, Gianfranco Amicucci

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Background: The treatment of patients with advanced or recurrent pelvic melanoma, which are often associated with lesions in the lower limbs, is still unsatisfactory and controversial. A simplified hypoxic pelvic and limb perfusion has been recently recommended to provide therapeutic options for palliation and possibly cure. Methods: A nonrandomized and noncontrolled phase II experimental study was performed in 11 patients with symptomatic unresectable recurrent melanoma of the pelvis and limb. Patients were submitted to hypoxic pelvic and limb perfusion with 25 mg/m2 of melphalan, 50 mg/m2 of cisplatin, 300 mg/m2 of dacarbazine, and 75 mg/m2 of epirubicin by means of a simplified balloon occlusion technique. Response rate and time to disease progresion were the primary endpoints; overall survival was the secondary endpoint. Results: During the procedures there were no technical, hemodynamic, or vascular complications, and no deaths occurred during surgery or in the postoperative period. Response rate was 82% (95% confidence interval, 58% to 100%). Median time to disease progression was 12 months (range 9 to 30 months). Three-year overall survival was 34%. Conclusions: Hypoxic pelvic and limb perfusion is a safe and good palliative treatment for patients with unresectable recurrent melanoma. Further studies are necessary to to confirm these data and to establish if refinements can be made with acceptable toxicity.

Original languageEnglish
Pages (from-to)28-36
Number of pages9
JournalAmerican Journal of Surgery
Volume183
Issue number1
DOIs
Publication statusPublished - 2002

Fingerprint

Melanoma
Extremities
Perfusion
Balloon Occlusion
Epirubicin
Dacarbazine
Melphalan
Survival
Therapeutics
Pelvis
Palliative Care
Postoperative Period
Cisplatin
Blood Vessels
Disease Progression
Lower Extremity
Hemodynamics
Confidence Intervals

Keywords

  • Hypoxia
  • Locoregional chemotherapy
  • Melanoma
  • Melphalan
  • Perfusion
  • Stop flow

ASJC Scopus subject areas

  • Surgery

Cite this

Deliberate hypoxic pelvic and limb chemoperfusion in the treatment of recurrent melanoma. / Guadagni, Stefano; Russo, Filippo; Rossi, Carlo Riccardo; Pilati, Pier Luigi; Miotto, Diego; Fiorentini, Giammaria; Deraco, Marcello; Santinami, Mario; Palumbo, Giancarlo; Valenti, Marco; Amicucci, Gianfranco.

In: American Journal of Surgery, Vol. 183, No. 1, 2002, p. 28-36.

Research output: Contribution to journalArticle

Guadagni, S, Russo, F, Rossi, CR, Pilati, PL, Miotto, D, Fiorentini, G, Deraco, M, Santinami, M, Palumbo, G, Valenti, M & Amicucci, G 2002, 'Deliberate hypoxic pelvic and limb chemoperfusion in the treatment of recurrent melanoma', American Journal of Surgery, vol. 183, no. 1, pp. 28-36. https://doi.org/10.1016/S0002-9610(01)00841-8
Guadagni, Stefano ; Russo, Filippo ; Rossi, Carlo Riccardo ; Pilati, Pier Luigi ; Miotto, Diego ; Fiorentini, Giammaria ; Deraco, Marcello ; Santinami, Mario ; Palumbo, Giancarlo ; Valenti, Marco ; Amicucci, Gianfranco. / Deliberate hypoxic pelvic and limb chemoperfusion in the treatment of recurrent melanoma. In: American Journal of Surgery. 2002 ; Vol. 183, No. 1. pp. 28-36.
@article{c5074bd187c044ed9d8c199fe7f3fe0f,
title = "Deliberate hypoxic pelvic and limb chemoperfusion in the treatment of recurrent melanoma",
abstract = "Background: The treatment of patients with advanced or recurrent pelvic melanoma, which are often associated with lesions in the lower limbs, is still unsatisfactory and controversial. A simplified hypoxic pelvic and limb perfusion has been recently recommended to provide therapeutic options for palliation and possibly cure. Methods: A nonrandomized and noncontrolled phase II experimental study was performed in 11 patients with symptomatic unresectable recurrent melanoma of the pelvis and limb. Patients were submitted to hypoxic pelvic and limb perfusion with 25 mg/m2 of melphalan, 50 mg/m2 of cisplatin, 300 mg/m2 of dacarbazine, and 75 mg/m2 of epirubicin by means of a simplified balloon occlusion technique. Response rate and time to disease progresion were the primary endpoints; overall survival was the secondary endpoint. Results: During the procedures there were no technical, hemodynamic, or vascular complications, and no deaths occurred during surgery or in the postoperative period. Response rate was 82{\%} (95{\%} confidence interval, 58{\%} to 100{\%}). Median time to disease progression was 12 months (range 9 to 30 months). Three-year overall survival was 34{\%}. Conclusions: Hypoxic pelvic and limb perfusion is a safe and good palliative treatment for patients with unresectable recurrent melanoma. Further studies are necessary to to confirm these data and to establish if refinements can be made with acceptable toxicity.",
keywords = "Hypoxia, Locoregional chemotherapy, Melanoma, Melphalan, Perfusion, Stop flow",
author = "Stefano Guadagni and Filippo Russo and Rossi, {Carlo Riccardo} and Pilati, {Pier Luigi} and Diego Miotto and Giammaria Fiorentini and Marcello Deraco and Mario Santinami and Giancarlo Palumbo and Marco Valenti and Gianfranco Amicucci",
year = "2002",
doi = "10.1016/S0002-9610(01)00841-8",
language = "English",
volume = "183",
pages = "28--36",
journal = "American Journal of Surgery",
issn = "0002-9610",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Deliberate hypoxic pelvic and limb chemoperfusion in the treatment of recurrent melanoma

AU - Guadagni, Stefano

AU - Russo, Filippo

AU - Rossi, Carlo Riccardo

AU - Pilati, Pier Luigi

AU - Miotto, Diego

AU - Fiorentini, Giammaria

AU - Deraco, Marcello

AU - Santinami, Mario

AU - Palumbo, Giancarlo

AU - Valenti, Marco

AU - Amicucci, Gianfranco

PY - 2002

Y1 - 2002

N2 - Background: The treatment of patients with advanced or recurrent pelvic melanoma, which are often associated with lesions in the lower limbs, is still unsatisfactory and controversial. A simplified hypoxic pelvic and limb perfusion has been recently recommended to provide therapeutic options for palliation and possibly cure. Methods: A nonrandomized and noncontrolled phase II experimental study was performed in 11 patients with symptomatic unresectable recurrent melanoma of the pelvis and limb. Patients were submitted to hypoxic pelvic and limb perfusion with 25 mg/m2 of melphalan, 50 mg/m2 of cisplatin, 300 mg/m2 of dacarbazine, and 75 mg/m2 of epirubicin by means of a simplified balloon occlusion technique. Response rate and time to disease progresion were the primary endpoints; overall survival was the secondary endpoint. Results: During the procedures there were no technical, hemodynamic, or vascular complications, and no deaths occurred during surgery or in the postoperative period. Response rate was 82% (95% confidence interval, 58% to 100%). Median time to disease progression was 12 months (range 9 to 30 months). Three-year overall survival was 34%. Conclusions: Hypoxic pelvic and limb perfusion is a safe and good palliative treatment for patients with unresectable recurrent melanoma. Further studies are necessary to to confirm these data and to establish if refinements can be made with acceptable toxicity.

AB - Background: The treatment of patients with advanced or recurrent pelvic melanoma, which are often associated with lesions in the lower limbs, is still unsatisfactory and controversial. A simplified hypoxic pelvic and limb perfusion has been recently recommended to provide therapeutic options for palliation and possibly cure. Methods: A nonrandomized and noncontrolled phase II experimental study was performed in 11 patients with symptomatic unresectable recurrent melanoma of the pelvis and limb. Patients were submitted to hypoxic pelvic and limb perfusion with 25 mg/m2 of melphalan, 50 mg/m2 of cisplatin, 300 mg/m2 of dacarbazine, and 75 mg/m2 of epirubicin by means of a simplified balloon occlusion technique. Response rate and time to disease progresion were the primary endpoints; overall survival was the secondary endpoint. Results: During the procedures there were no technical, hemodynamic, or vascular complications, and no deaths occurred during surgery or in the postoperative period. Response rate was 82% (95% confidence interval, 58% to 100%). Median time to disease progression was 12 months (range 9 to 30 months). Three-year overall survival was 34%. Conclusions: Hypoxic pelvic and limb perfusion is a safe and good palliative treatment for patients with unresectable recurrent melanoma. Further studies are necessary to to confirm these data and to establish if refinements can be made with acceptable toxicity.

KW - Hypoxia

KW - Locoregional chemotherapy

KW - Melanoma

KW - Melphalan

KW - Perfusion

KW - Stop flow

UR - http://www.scopus.com/inward/record.url?scp=0036178729&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036178729&partnerID=8YFLogxK

U2 - 10.1016/S0002-9610(01)00841-8

DO - 10.1016/S0002-9610(01)00841-8

M3 - Article

C2 - 11869699

AN - SCOPUS:0036178729

VL - 183

SP - 28

EP - 36

JO - American Journal of Surgery

JF - American Journal of Surgery

SN - 0002-9610

IS - 1

ER -